KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Receivables (2016 - 2025)

Sarepta Therapeutics has reported Receivables over the past 16 years, most recently at $502.3 million for Q4 2025.

  • For Q4 2025, Receivables fell 21.09% year-over-year to $502.3 million; the TTM value through Dec 2025 reached $502.3 million, down 21.09%, while the annual FY2025 figure was $502.3 million, 21.09% down from the prior year.
  • Receivables for Q4 2025 was $502.3 million at Sarepta Therapeutics, down from $524.4 million in the prior quarter.
  • Over five years, Receivables peaked at $714.6 million in Q1 2025 and troughed at $133.3 million in Q1 2021.
  • A 5-year average of $356.0 million and a median of $320.0 million in 2023 define the central range for Receivables.
  • On a YoY basis, Receivables climbed as much as 74.76% in 2025 and fell as far as 21.09% in 2025.
  • Year by year, Receivables stood at $153.0 million in 2021, then skyrocketed by 67.58% to $256.4 million in 2022, then surged by 67.76% to $430.1 million in 2023, then skyrocketed by 48.0% to $636.6 million in 2024, then fell by 21.09% to $502.3 million in 2025.
  • Business Quant data shows Receivables for SRPT at $502.3 million in Q4 2025, $524.4 million in Q3 2025, and $600.6 million in Q2 2025.